Drug-eluting stents and acute myocardial infarction:A lethal combination or friends?
Drug-eluting stents and acute myocardial infarction:A lethal combination or friends?作者机构:Thorax InstituteDepartment of CardiologyHospital ClinicUniversity of Barcelona
出 版 物:《World Journal of Cardiology》 (世界心脏病学杂志(英文版)(电子版))
年 卷 期:2014年第6卷第9期
页 面:929-938页
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题:ST-segment elevation myocardial infarction Drug-eluting stents Stent thrombosis Sirolimus drug-eluting Paclitaxel drug-eluting stents Zotarolimus-eluting stents Zotarolimus-eluting stents Bioresorbable vascular scaffold
摘 要:Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients presenting with ST-segment elevation myocardial infarction(STEMI). First generation drug-eluting stents(DES),(sirolimus drug-eluting stents and paclitaxel drug-eluting stents), reduce the risk of restenosis and target vessel revascularization compared to bare metal stents. However, stent thrombosis emerged as a major safety concern with first generation DES. In response to these safety issues, second generation DES were developed with different drugs, improved stent platforms and more biocompatible durable or bioabsorbable polymeric coating. This article presents an overview of safety and efficacy of the first and second generation DES in STEMI.